Bringing a new drug to market is a decade-long, billion-dollar gamble with a staggering failure rate. The process of identifying viable compounds and designing efficient clinical trials remains a primary bottleneck, delaying critical new therapies from reaching the patients who need them.

Pharmaceutical supply chains are a fragile, high-stakes global network. Ensuring the right medicine is in the right place at the right time—often while maintaining a strict cold chain and preventing counterfeits—is a constant battle against disruption. Manual planning cannot keep pace with global uncertainty.

Once a drug is on the market, ensuring patient safety (pharmacovigilance) requires monitoring a massive and ever-growing volume of data from sources like clinical reports, patient forums, and electronic health records. Manually detecting adverse drug reactions in this sea of information is slow and reactive.